Powerhouse consulting firm McKinsey & Co. promoted a questionable strategy to increase the sales of OxyContin — giving distributors a rebate for every overdose tied to the pills they sold, according to a report.
A trove of documents released in a bankruptcy court case showed McKinsey’s role in advising the Sackler family, which owned Oxy maker Purdue Pharma, as opioid deaths mounted, The New York Times reported.
McKinsey, in a 2017 presentation, estimated that 2,484 customers of drug store chain CVS would overdose or become addicted to opioids in 2019 and it would pay a rebate of $14,810 “per event,” The Times reported.
CVS said it did not receive any rebates.
Purdue Pharma pleaded guilty Tuesday to three criminal charges for its role the national opioid epidemic.
Some of McKinsey’s strategy came to light last year in a court case filed by Massachusetts which accused the Sackler family of creating and making money off the epidemic.
The suit claimed McKinsey was helping to “counter the emotional messages from mothers with teenagers that overdosed in [sic] OxyContin.”